Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by NotinKansason May 01, 2023 1:01am
128 Views
Post# 35422202

RE:RE:RE:RE:72% CR at any point in time.

RE:RE:RE:RE:72% CR at any point in time.I agree that the 12 undertreated should be removed from the analysis, but they are not removed from the current data presentation at all. Not at 90 days and not at any of the other time points. From those 12, two made it CR all the way through to 450 days and one ended IR at 450 days (see MD&A of 28 April 2022). They are in the swimmers’ plot. The others will be there as well, up until the last assessment they received.

Key to understanding the plot is acknowledging that it shows only assessments that have actually taken place, not the number of patients that – timewise – have reached a certain stage. There are currently 31 (plus or minus 1) patients who have been long enough in the trial to have timewise qualified for their 450 days assessment. According to the plot, however, only 12 have actually received that assessment. The other 19 have not received it and, so it would seem, are also not going to get that assessment. We can only speculate about the reasons for that: trial protocol, patients stepping out voluntarily, or something else.

From a trial perspective there is also little point in continuing assessments once a patient is (still) NR at 270 days. They are very unlikely to change to IR or CR after that and therefore will not further contribute to Objective 1 or 2. You could say it’s economic.

<< Previous
Bullboard Posts
Next >>